Scientists test Triple-Threat attack on deadly brain cancer
NCT ID NCT03212742
Summary
This study is testing whether adding a drug called olaparib to the standard radiation and chemotherapy treatment can help patients with aggressive, inoperable brain tumors live longer. The goal is to see if olaparib makes the cancer cells more sensitive to the damaging effects of radiation and chemotherapy. The trial will first find the safest dose and then see if this three-part combination improves 12-month survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CH du Havre
Le Havre, France
-
CHU
Amiens, France
-
CHU
Bordeaux, France
-
Centre Eugène Marquis
Rennes, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Guillaume le Conquérant
Le Havre, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
-
Centre léon Bérard
Lyon, France
-
GHBS
Lorient, France
-
Hôpitaux universitaires La Pitié Salpétrière - Charles Foix
Paris, France
-
Institut Claudius Regaud
Toulouse, France
-
Institut Curie
Paris, France
-
Institut de Cancérologie de l'Ouest
Angers, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
Conditions
Explore the condition pages connected to this study.